These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11938071)

  • 1. [Severe acute hepatitis induced by alendronate].
    Carrère C; Duval JL; Godard B; De Jaureguiberry JP; Ciribilli JM
    Gastroenterol Clin Biol; 2002 Feb; 26(2):179-80. PubMed ID: 11938071
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis after alendronate.
    Lieverse RJ
    Neth J Med; 1998 Dec; 53(6):271-2. PubMed ID: 9883006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver damage due to alendronate.
    Halabe A; Lifschitz BM; Azuri J
    N Engl J Med; 2000 Aug; 343(5):365-6. PubMed ID: 10928896
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alendronate-induced hepatocellular lesion].
    de La Serna Higuera C; Pérez Villoria A; Rodríguez Gómez S; Martínez Moreno J; Betancourt González A; Martín Arribas M
    Gastroenterol Hepatol; 2001 May; 24(5):244-6. PubMed ID: 11412594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity induced by alendronate therapy.
    Yanik B; Turkay C; Atalar H
    Osteoporos Int; 2007 Jun; 18(6):829-31. PubMed ID: 17226065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate: a bisphosphonate for treatment of osteoporosis.
    Kirk JK; Spangler JG
    Am Fam Physician; 1996 Nov; 54(6):2053-60. PubMed ID: 8900364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
    Chailurkit LO; Jongjaroenprasert W; Rungbunnapun S; Ongphiphadhanakul B; Sae-tung S; Rajatanavin R
    J Bone Miner Metab; 2003; 21(6):421-7. PubMed ID: 14586800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [FACT study: benefits of alendronate].
    MMW Fortschr Med; 2005 Jan; 147(1-2):52-3. PubMed ID: 15704574
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term insurance for the bones. Effective and safe over 7 years].
    MMW Fortschr Med; 2002 Jun; 144(25):52-3. PubMed ID: 12141293
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
    N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.
    Mersereau JE; Khouri C; Jaffe RB
    Fertil Steril; 2010 Aug; 94(3):1138-40. PubMed ID: 20056199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous bilateral atypical femoral fractures after alendronate therapy.
    Zafeiris CP; Stathopoulos IP; Kourkoumelis G; Gkikas E; Lyritis GP
    J Musculoskelet Neuronal Interact; 2012 Dec; 12(4):262-4. PubMed ID: 23196269
    [No Abstract]   [Full Text] [Related]  

  • 15. Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features.
    Ryan JM; Kelsey P; Ryan BM; Mueller PR
    Radiology; 1998 Feb; 206(2):389-91. PubMed ID: 9457190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of alendronate treatment for osteoporosis in postmenopausal women.
    Ruggiero SL; Mehrotra B
    N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15250063
    [No Abstract]   [Full Text] [Related]  

  • 17. Renal function and bisphosphonate safety.
    Ott SM; Drueke T; Elder G; Fukagawa M; Jorgetti V; Langman CB; Moe S; McCann L; Wang AY; Weisinger J; Wheeler D
    J Bone Miner Res; 2008 Mar; 23(3):453-4; author reply 455. PubMed ID: 17967135
    [No Abstract]   [Full Text] [Related]  

  • 18. Ten years' experience with alendronate for osteoporosis in postmenopausal women.
    Bone HG; Hosking D; Devogelaer JP; Tucci JR; Emkey RD; Tonino RP; Rodriguez-Portales JA; Downs RW; Gupta J; Santora AC; Liberman UA;
    N Engl J Med; 2004 Mar; 350(12):1189-99. PubMed ID: 15028823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal osteoporosis and alendronate.
    Pérez-López FR
    Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.